fbpx

Rare cancers

Recognising Diverse Needs during NAIDOC Week: Tracy’s Journey with Gynaecological Cancer

During National Aboriginal and Islanders Day Observance Committee (NAIDOC) Week, we celebrate Tracy's journey. Tracy, a proud Aboriginal woman, embodies determination and leadership. She has always been a go-getter. Unlike many in her community, she is [...]

Recognising Diverse Needs during NAIDOC Week: Tracy’s Journey with Gynaecological Cancer2024-07-09T15:54:47+10:00

New global therapy now approved for Australian patients with Leiomyosarcoma

An additional chemotherapy option for people with advanced leiomyosarcoma is now available on the Pharmaceutical Benefits Scheme (PBS). Trabectedin, (brand name - Yondelis) offers renewed hope for patients facing this rare and challenging sarcoma cancer. [...]

New global therapy now approved for Australian patients with Leiomyosarcoma2023-10-18T11:44:07+11:00

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs

Led by ANZGOG co-founder Professor Michael Friedlander AM, PARAGON was one of ANZGOG's first practice-changing studies. The publications arising from the insights and data collected because of this pivotal trial continue to contribute to research on [...]

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs2023-10-18T11:45:30+11:00

PEACE trial opens to recruitment

ANZGOG’s new study for patients with advanced gynaecological cancer, PEACE, has officially opened to recruitment after activating its first site, Canberra Hospital. Led by Principal Investigator Dr Alison Davis in Australia, the international study [...]

PEACE trial opens to recruitment2023-10-18T12:01:14+11:00

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment

EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Dr Katrin Sjoquist, Medical Oncologist [...]

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment2022-07-01T11:34:46+10:00

HyNOVA trial opens to recruitment

The HyNOVA study has officially opened to recruitment after activating its first site, Peter MacCallum Cancer Centre and Royal Women’s Hospital. Researchers of the HyNOVA study are seeking 80 participants at five sites across [...]

HyNOVA trial opens to recruitment2021-09-02T06:02:56+10:00

ANZGOG Director awarded for her significant contribution as a medical oncology clinician

ANZGOG Director Professor Clare Scott has been awarded the Medical Oncology Group of Australia (MOGA) and Novartis Oncology Cancer Achievement Award. Professor Clare Scott, Medical Oncologist Prof Clare Scott is a clinical [...]

ANZGOG Director awarded for her significant contribution as a medical oncology clinician2021-11-10T23:05:11+11:00
Go to Top